Oculis (NASDAQ:OCS) Stock Price Expected to Rise, HC Wainwright Analyst Says

by · The Markets Daily

Oculis (NASDAQ:OCS – Get Free Report) had its target price hoisted by equities researchers at HC Wainwright from $26.00 to $39.00 in a research report issued on Friday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 290.78% from the stock’s current price.

A number of other research analysts also recently commented on the company. Guggenheim dropped their price target on Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Needham & Company LLC cut their price target on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, June 1st. Stifel Nicolaus decreased their price objective on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Finally, Wall Street Zen upgraded shares of Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $39.44.

Get Our Latest Stock Report on Oculis

Oculis Stock Performance

Shares of NASDAQ:OCS opened at $9.98 on Friday. The firm has a market cap of $578.64 million, a PE ratio of -5.74 and a beta of 0.52. Oculis has a 12-month low of $9.65 and a 12-month high of $34.47. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average price is $12.10 and its two-hundred day moving average price is $19.01.

Oculis (NASDAQ:OCS – Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $0.38 million during the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. Equities research analysts predict that Oculis will post -2.01 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Braidwell LP acquired a new position in Oculis in the 2nd quarter worth about $11,570,000. Folketrygdfondet bought a new stake in shares of Oculis during the fourth quarter worth about $3,651,000. Propel Bio Management LLC acquired a new position in shares of Oculis in the fourth quarter valued at approximately $3,452,000. NEXTBio Capital Management LP bought a new position in Oculis in the 4th quarter valued at approximately $2,991,000. Finally, Simplify Asset Management Inc. bought a new position in Oculis in the 4th quarter valued at approximately $1,972,000. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

(Get Free Report)

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis’ pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery.

See Also